Dynamic Technology Lab Private Ltd Purchases Shares of 6,190 Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Dynamic Technology Lab Private Ltd has acquired 6,190 shares of Jazz Pharmaceuticals PLC, representing a new investment valued at approximately $768,000.
• Several large investors, including Dimensional Fund Advisors LP and JPMorgan Chase & Co., have increased their stakes in Jazz Pharmaceuticals during the first quarter of the year.
• Jazz Pharmaceuticals experienced a disappointing earnings report, with a loss of $8.25 per share for the quarter, missing analyst expectations of $5.61 by a significant margin.

Dynamic Technology Lab Private Ltd acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,190 shares of the specialty pharmaceutical company's stock, valued at approximately $768,000.

Other large investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its stake in Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after acquiring an additional 293,360 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals by 4.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock valued at $206,343,000 after purchasing an additional 74,501 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock valued at $165,245,000 after purchasing an additional 391,660 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Jazz Pharmaceuticals by 8.3% in the 4th quarter. Vestal Point Capital LP now owns 975,000 shares of the specialty pharmaceutical company's stock valued at $120,071,000 after purchasing an additional 75,000 shares in the last quarter. Finally, Perpetual Ltd lifted its position in shares of Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after purchasing an additional 357,784 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JAZZ shares. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price on the stock. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Finally, Royal Bank Of Canada raised their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $178.67.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $129.85 on Tuesday. The stock has a market cap of $7.88 billion, a P/E ratio of -19.29, a P/E/G ratio of 8.03 and a beta of 0.24. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a 50 day moving average of $117.16 and a two-hundred day moving average of $116.73. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the prior year, the company earned $5.30 EPS. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.